CELL INTELLIGENCE · 肿瘤细胞治疗研究

克服卵巢癌治疗耐药：从分子机制到新兴治疗策略

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.

靶向 PD-L1 和 ErbB2（HER2）的双重 CAR-NK 细胞表现出协同 CAR 信号传导并抵抗实体瘤异质性

Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.

同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。

嵌合抗原受体 NK 细胞疗法治疗首次复发的上皮性卵巢癌：荷兰的早期卫生经济学评价

Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlan

CAR-NK 细胞疗法对铂敏感 EOC 可能具有成本效益。

CAR-T 与 CAR-NK 细胞疗法治疗卵巢癌的当前进展

Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.

重定位抗间皮素 CAR-NK 免疫治疗用于结直肠癌

Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.

我们的结果提供了临床前证据，表明表达高水平间皮素的结直肠癌亚群可被基于 MSLN-CAR 的免疫治疗有效靶向。